Novartis Scemblix®, with novel mechanism of action, approved by ...
Scemblix® (asciminib) approved in Europe for Ph+ CML-CP, showing a 25.5% MMR rate vs. 13.2% for Bosulif®, with lower discontinuation rates due to adverse reactions. It targets the ABL myristoyl pocket, offering a new option for patients resistant or intolerant to prior TKIs.
Related Clinical Trials
Reference News
Scemblix® (asciminib) approved in Europe for Ph+ CML-CP, showing a 25.5% MMR rate vs. 13.2% for Bosulif®, with lower discontinuation rates due to adverse reactions. It targets the ABL myristoyl pocket, offering a new option for patients resistant or intolerant to prior TKIs.
Novartis' Scemblix (asciminib) approved by EC for Ph+ CML-CP treatment in adults previously treated with ≥2 TKIs, based on phase III ASCEMBL study showing higher response and lower discontinuation rates vs. Bosulif. Scemblix, a STAMP inhibitor, also FDA-approved, strengthens Novartis' oncology portfolio amid strategic focus on core pharma and therapeutic areas.
Scemblix (asciminib) received FDA approval for treating chronic myeloid leukemia (CML) in patients resistant or intolerant to at least two TKIs, showing superior MMR rates and lower discontinuation due to side effects compared to Bosulif. It's also approved for CML patients with the T315I mutation, offering a novel STAMP inhibitor mechanism.